Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Phase 1 Completed
12 enrolled 12 charts
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Phase 1 Completed
15 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Phase 2 Completed
41 enrolled 15 charts
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase 1/2 Completed
140 enrolled 23 charts
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Phase 2 Completed
22 enrolled 15 charts
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed
1,720 enrolled
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed
482 enrolled
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Phase 2 Completed
19 enrolled 12 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Phase 2 Completed
46 enrolled 13 charts
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Phase 1/2 Completed
78 enrolled 11 charts
Informed Consent in Pediatric Cancer Trials
Completed
1 enrolled
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
178 enrolled 6 charts
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase 2 Completed
100 enrolled
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 2 Completed
116 enrolled 8 charts
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase 2 Completed
120 enrolled
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Phase 2 Completed
15 enrolled 7 charts
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Alanosine in Treating Patients With Cancer
Phase 2 Completed
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
Phase 1 Completed
36 enrolled
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
Phase 2 Completed
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Docetaxel in Treating Children With Recurrent Solid Tumors
Phase 2 Completed
20 enrolled
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Phase 2 Completed
125 enrolled
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
Phase 2 Completed
80 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
Phase 1 Completed
120 enrolled
Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study
Phase 3 Completed
260 enrolled
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
Phase 1 Completed
24 enrolled